Pharmafile Logo
Pharmafocus logo
Advanced Search

Sanofi

Showing 15 posts of 579 posts found.

Sanofi's Multaq (dronedarone)

EMA widens safety review of Sanofi’s Multaq

July 12, 2011
Sales and Marketing Multaq, Sanofi

European regulators are to extend their assessment of the risks associated with Sanofi’s atrial fibrillation (AF) medicine Multaq to take …

News
Sanofi

Sanofi sells dermatology unit for $425m

July 11, 2011
Manufacturing and Production, Sales and Marketing Canada, Dermik, Sanofi, Valeant, dermatology

Sanofi has sold its Canadian dermatology unit Dermik for $425 million in order to concentrate on key growth areas like …

News
Sanofi

Sanofi launches Jevtana in UK

July 6, 2011
Sales and Marketing Jevtana, Sanofi, prostate cancer

Sanofi has launched its promising advanced prostate cancer drug Jevtana in the UK following EMA approval in March. Jevtana (cabazitaxel) …

News
Sanofi

Sanofi to research new types of antibiotics

July 6, 2011
Research and Development Antibiotics, Rib-X Pharmaceuticals, Sanofi, research and development news

Sanofi has signed a research collaboration with Rib-X Pharmaceuticals to investigate new types of antibiotics. The French pharma company has …

News

Sanofi to boost early-stage research with ‘real world’ evidence

June 23, 2011
Research and Development Sanofi, patient data, pharma research

Sanofi is aiming to maximise its R&D investment by including ‘real world’ evidence in its product development strategy. The company …

News
Sanofi headquarters

Sanofi signs regenerative medicines collaboration

June 16, 2011
Research and Development Audion, Sanofi, hearing loss

Sanofi has signed a research pact with Audion Therapeutics to develop regenerative medicines for hearing loss. The company’s two-year deal …

News

Bayer contraceptive advert breaches Code of Practice

May 27, 2011
Medical Communications ABPI Code of Practice, Bayer, Multaq, Sanofi, Yasmin

Bayer Healthcare has been singled out for “particular censure” by the PMCPA, the body which regulates the ABPI Code of …

News

Sanofi strikes Crohn’s deal with Glenmark

May 16, 2011
Research and Development Crohn’s disease, Glenmark, Sanofi

Sanofi has signed a deal with Indian drug maker Glenmark Pharmaceuticals to develop a new treatment for Crohn’s Disease. The …

News
Sanofi's new logo

Sanofi name change sees Aventis dropped

May 9, 2011
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, Sanofi-Aventis

Sanofi-Aventis will now just be known as Sanofi after the French pharma company’s shareholders agreed to change its name. Following …

News
Sanofi headquarters

Sanofi abandons $375m oral diabetes deal

May 9, 2011
Sales and Marketing Metabolex, Sanofi, diabetes

Sanofi has terminated its $375 million deal with US biotech Metabolex to develop a novel oral anti-diabetic treatment. The French …

News

Sanofi seals Genzyme deal for $20 billion

February 16, 2011
Research and Development, Sales and Marketing Genzyme, Sanofi

Sanofi-Aventis has finally agreed a deal to buy Genzyme for $20.1 billion after eight months of wrangling with the US …

News

Generics force Sanofi into standstill

February 9, 2011
Sales and Marketing 2010 pharma results, Jevtana, Multaq, Sanofi, Sanofi-Aventis, generics

An onslaught of generic competition combined with healthcare cuts in the US and Europe meant Sanofi-Aventis’ revenues were brought to …

News

Diabetes success for Sanofi, disappointment for Roche

February 2, 2011
Roche, Sanofi, diabetes

The contrasting fortunes of two new diabetes became clear today, with Sanofi-Aventis lixisenatide performing well, as Roche abandoned taspoglutide.Sanofi’s lixisenatide, …

News

Sanofi – Genzyme deal edges closer

February 1, 2011
Sales and Marketing Genzyme, Lemtrada, Sanofi

Sanofi-Aventis has entered into a confidentiality agreement with Genzyme to discuss the prospects of Lemtrada, which suggests a deal could …

News

Sanofi buys into cancer antibody research

January 26, 2011
Research and Development Cancer, Oxford Biotherapeutics, Sanofi, Sanofi-Aventis, antibody drug conjugate, cancer research

Sanofi-Aventis has bought a global licence to develop and commercialise one of Oxford BioTherapeutics’ (OBT) oncology programmes. For an undisclosed …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025